• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Capricor Therapeutics, Inc. (Amendment)

    8/3/21 4:28:14 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPR alert in real time by email
    SC 13G/A 1 tm2123929d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    Amendment No. 1* (EXIT FILING)

     

    Under the Securities Exchange Act of 1934

     

    CAPRICOR THERAPEUTICS, INC.
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
    14070B309
    (CUSIP Number)
     
    July 28, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Larry N. Feinberg

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ☐

    (b)  ☐

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    0

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    0

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

      ☐

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

             

     

    1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Oracle Partners, L.P.

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ☐

    (b)  ☐

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    0

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    0

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

      ☐

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

             

     

    1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Oracle Institutional Partners, L.P.

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ☐

    (b)  ☐

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    0

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    0

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

      ☐

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

             

      

    1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Oracle Ten Fund, L.P.

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ☐

    (b)  ☐

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    0

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    0

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

      ☐

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

             

     

    1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Oracle Associates, LLC

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ☐

    (b)  ☐

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    0

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    0

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

      ☐

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%*

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

             

      

    1

     

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Oracle Investment Management, Inc.

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a)  ☐

    (b)  ☐

     

    3

     

    SEC USE ONLY

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    0

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    0

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

      ☐

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.00%*

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    CO

             

      

    This Amendment No. 1 to Schedule 13G (this “Amendment No. 1”) is being filed with respect to the Common Stock, par value $0.001 (the “Common Stock”) of Capricor Therapeutics, Inc., a Delaware corporation (the “Issuer”), to amend the Schedule 13G filed on February 8, 2021, (as so amended, the “Schedule 13G”). This Amendment No. 1 is being filed on behalf of Oracle Partners, L.P., a Delaware limited partnership (“Oracle Partners”), Oracle Ten Fund, L.P., a Delaware limited partnership (“Oracle Ten Fund”), Oracle Institutional Partners, L.P., a Delaware limited partnership (“Institutional Partners” and, collectively with Oracle Partners and Oracle Ten Fund, the “Oracle Partnerships”), Oracle Associates, LLC, a Delaware limited liability company and the general partner of the Oracle Partnerships (“Oracle Associates”), Oracle Investment Management, Inc., a Delaware corporation and the investment manager to the Oracle Partnerships (the “Investment Manager”), and Larry N. Feinberg, the managing member of Oracle Associates, the sole shareholder and the director and president of the Investment Manager (each of the foregoing, a “Reporting Person” and collectively, the “Reporting Persons”). Capitalized terms used but not defined herein have the meaning ascribed thereto in the Schedule 13G. This Amendment constitutes an exit filing of the Reporting Persons.

     

    Item 4. Ownership:

      

      A. Larry N. Feinberg

     

      (a) Amount beneficially owned: 0
      (b) Percent of class: 0.00%
      (c) Number of shares as to which such person has:

     

      (i)    Sole power to vote or direct the vote: 0
      (ii)   Shared power to vote or direct the vote: 0
      (iii) Sole power to dispose or direct the disposition: 0
      (iv) Shared power to dispose or direct the disposition: 0

     

      B. Oracle Partners, L.P.

     

      (a) Amount beneficially owned: 0
      (b) Percent of class: 0.00%
      (c) Number of shares as to which such person has:

     

      (i)    Sole power to vote or direct the vote: 0
      (ii)   Shared power to vote or direct the vote: 0
      (iii) Sole power to dispose or direct the disposition: 0
      (iv) Shared power to dispose or direct the disposition: 0

     

      C. Oracle Institutional Partners, L.P.

     

      (a) Amount beneficially owned: 0
      (b) Percent of class: 0.00%
      (c) Number of shares as to which such person has:

     

      (i)    Sole power to vote or direct the vote: 0
      (ii)   Shared power to vote or direct the vote: 0
      (iii) Sole power to dispose or direct the disposition: 0
      (iv) Shared power to dispose or direct the disposition: 0

     

      D. Oracle Ten Fund, L.P.

     

      (a) Amount beneficially owned: 0
      (b) Percent of class: 0.00%
      (c) Number of shares as to which such person has:

     

      (i)    Sole power to vote or direct the vote: 0
      (ii)   Shared power to vote or direct the vote: 0
      (iii) Sole power to dispose or direct the disposition: 0
      (iv) Shared power to dispose or direct the disposition: 0

     

      E. Oracle Associates, LLC

     

      (a) Amount beneficially owned: 0
      (b) Percent of class: 0.00%
      (c) Number of shares as to which such person has:

     

      (i)    Sole power to vote or direct the vote: 0
      (ii)   Shared power to vote or direct the vote: 0
      (iii) Sole power to dispose or direct the disposition: 0
      (iv) Shared power to dispose or direct the disposition: 0

     

     

      F. Oracle Investment Management, Inc.

     

      (a) Amount beneficially owned: 0
      (b) Percent of class: 0.00%
      (c) Number of shares as to which such person has:

     

      (i)    Sole power to vote or direct the vote: 0
      (ii)   Shared power to vote or direct the vote: 0
      (iii) Sole power to dispose or direct the disposition: 0
      (iv) Shared power to dispose or direct the disposition: 0

     

    Item 5. Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 3, 2021

     

      /s/ Larry N. Feinberg
      Larry N. Feinberg, Individually
       
      ORACLE PARTNERS, L.P.
      By: ORACLE ASSOCIATES, LLC, its general partner
       
      By: /s/ Larry N. Feinberg
      Larry N. Feinberg, Managing Member
       
      ORACLE INSTITUTIONAL PARTNERS, L.P.
      By: ORACLE ASSOCIATES, LLC, its general partner
       
      By: /s/ Larry N. Feinberg
     

    Larry N. Feinberg, Managing Member

     

    ORACLE TEN FUND, L.P.

    By: ORACLE ASSOCIATES, LLC, its general partner

       
     

    By:

    /s/ Larry N. Feinberg

      Larry N. Feinberg, Managing Member
       
      ORACLE ASSOCIATES, LLC
       
      By: /s/ Larry N. Feinberg
      Larry N. Feinberg, Managing Member
       
      ORACLE INVESTMENT MANAGEMENT, INC.
       
      By: /s/ Larry N. Feinberg
      Larry N. Feinberg, President

     

     

    Get the next $CAPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAPR

    DatePrice TargetRatingAnalyst
    10/21/2024$35.00Overweight
    Piper Sandler
    5/17/2024$14.00Outperform
    Oppenheimer
    1/5/2024$8.00Overweight
    Cantor Fitzgerald
    10/26/2022$15.00Buy
    Ladenburg Thalmann
    1/31/2022$14.00 → $18.00Buy
    HC Wainwright & Co.
    10/11/2021$9.00 → $14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CAPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Capricor Therapeutics with a new price target

      Piper Sandler initiated coverage of Capricor Therapeutics with a rating of Overweight and set a new price target of $35.00

      10/21/24 7:35:33 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Capricor Therapeutics with a new price target

      Oppenheimer initiated coverage of Capricor Therapeutics with a rating of Outperform and set a new price target of $14.00

      5/17/24 7:29:53 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Capricor Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Capricor Therapeutics with a rating of Overweight and set a new price target of $8.00

      1/5/24 7:28:46 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

      SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

      11/8/24 9:00:23 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

      SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

      9/24/24 4:03:22 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

      SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

      8/23/24 4:01:31 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

      SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors. "Michael is an outstanding addition to Capricor's leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities," said Linda

      5/13/25 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

      SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024. "We are thrilled to be joining the Russell 2000® Index, a testament to our Company's progress across our pipeline marked by significant advancements in our lead program for the treatment of Duchenne muscular dystrophy," said Linda Marbán, Ph.D., Capricor's chief executive officer. "This milestone reflects Ca

      7/1/24 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

      SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry. "It is a pleasure to welcome Mike to our Board of Directors, who has an extraor

      9/6/23 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Financials

    Live finance-specific insights

    See more
    • Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025Recently completed mid-cycle review meeting with FDA with no significant deficiencies identified; late cycle meeting scheduled for June FDA has indicated intent to convene advisory committee meetingAppointed Dr. Michael Binks as Chief Medical Officer, bringing deep experience in neuromuscular and rare diseasesThe National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor's StealthX™ exosome vaccine in the

      5/13/25 4:05:00 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 13, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 73741Participants can use g

      5/6/25 9:15:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

      SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 19, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on March 19. Title:Capricor Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, March 19, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-18

      3/11/25 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CAPR
    SEC Filings

    See more

    $CAPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CAPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Marban Linda exercised 25,000 shares at a strike of $1.39 and disposed of 12,500 shares, increasing direct ownership by 6% to 211,104 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      3/5/25 5:00:13 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Bergmann Anthony exercised 2,500 shares at a strike of $1.39, increasing direct ownership by 44% to 8,223 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      3/4/25 7:00:17 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Litvack Frank exercised 25,000 shares at a strike of $1.39 and covered exercise/tax liability with 2,543 shares, increasing direct ownership by 21% to 129,839 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      3/4/25 7:00:13 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Capricor Therapeutics Inc.

      10-Q - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

      5/14/25 4:30:49 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

      5/13/25 4:06:28 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Capricor Therapeutics Inc.

      SCHEDULE 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

      4/30/25 10:58:05 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025Recently completed mid-cycle review meeting with FDA with no significant deficiencies identified; late cycle meeting scheduled for June FDA has indicated intent to convene advisory committee meetingAppointed Dr. Michael Binks as Chief Medical Officer, bringing deep experience in neuromuscular and rare diseasesThe National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor's StealthX™ exosome vaccine in the

      5/13/25 4:05:00 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

      SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors. "Michael is an outstanding addition to Capricor's leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities," said Linda

      5/13/25 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 13, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 73741Participants can use g

      5/6/25 9:15:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Nippon Shinyaku Co Ltd bought $14,999,998 worth of shares (2,798,507 units at $5.36), increasing direct ownership by 65% to 7,090,351 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      9/24/24 4:01:08 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Musket David B bought $1,128 worth of shares (410 units at $2.75), increasing direct ownership by 1% to 31,536 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      10/13/23 1:59:57 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collier Earl M Jr bought $28,300 worth of shares (10,000 units at $2.83), increasing direct ownership by 59% to 26,856 units (SEC Form 4)

      4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

      10/12/23 9:15:07 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care